Sergio Traversa | Source | CEO at Relmada Therapeutics

This patent, which has previously been granted in the U.S., EU, Australia, China, Hong Kong, Mexico, and South Korea, advances our objective of further strengthening our intellectual property portfolio in multiple key markets around the world. Canada represents a significant market opportunity for Relmada, as published research indicates that the 12 months' prevalence rate of major depressive disorder (MDD) in Canada was 4.7%, and the lifetime prevalence rate was 11.2%¹. We look forward to initiating our Phase 3 program for REL-1017 for the adjunctive treatment of MDD in the fourth quarter of this year.